Was intressted and found this on the web ...

International Pharmaceutics Target on Private Healthcare Market ( 2007-12-11 )
Reported by Huang Yi-Hsin
After a series of NHI price cuts, international drug manufacturers started directing efforts to private healthcare market. New OTC products have been introduced into the market in the previous quarter by many international drug manufacturers, including Wyeth, GSK and Novartis.
Panadol, manufactured by GSK, is a well-know pain and cold relief medicine in Taiwan. GSK launched Panadol Patch in the OTC market in August 2006. Within a year, this product has become the best selling product in its category. Hsieh Chia-Rong from the GSK expressed that Panadol Patch is distinct from other patches for external use because it contains diclofenac sodium and is categorized as an instruction drug
GSK increased the proportion of OTC products from the end of last year. So far, Panadol Patch accounted for under 10% of the total OTC market; and GSK hopes to increase its market share by using its brand assets.
Wyeth Taiwan also drew their attention to the OTC market for cold-relief products as the OTC market has been expanding over the past few years. Wyeth Taiwan has had a 10% annual growth in the OTC market over the past five years.
As for Novartis, since the OTC department became autonomous, the sales have increased by 30% in China. Novatis Taiwan expressed that though prescription drugs are still their major market, the OTC department is very active and they already launched two new products this autumn, hoping to boost the sales by 10%.
The BNHI announced the 5th PV survey recheck results in October and cut drug expenditures by NT$6 billion. Adding up the previous announcement, total NT$15 billion was squeezed from drug procurements. Under the circumstance, the OTC market may become another major battle ground for drug manufacturers.
【2007-12-11/ Economic Daily /Page C8】

Now if you can only GET some